Proactiveinvestors United Kingdom Xenetic Biosciences articles

Xenetic Biosciences, African Medical Investments and e-Therapeutics to appear at Proactive Investors One2One Forum

Mon, 07 Nov 2011 13:55:00 +0000

We have an exciting line-up of companies at the Proactive Investors One2One Forum in London on Tuesday (November 8), which has attracted an incredible amount of interest. So this is a call to arms. If you haven't signed up now do so soon to avoid disappointment. Appearing are Xenetic Biosciences, African Medical Investments and e-Therapeutics.

Lipoxen's acquisition and Russian partnership utterly transforms drug developer

Thu, 04 Aug 2011 07:46:00 +0100

Lipoxen has this morning unveiled an acquisition and an agreement with the Russian state-owned nanotechnology investment company that will utterly transform the bio-pharmaceuticals group.

Lipoxen drug pipeline progressing nicely

Mon, 20 Sep 2010 08:26:00 +0100

The development of anaemia treatment ErepoXen is progressing well. Its other key product, long-acting insulin SuliXen, remains on track to enter phase II clinical trials in the final quarter of this year.

Lipoxen's Ties With Baxter Strengthen After US$4 million Deal

Thu, 16 Sep 2010 07:00:00 +0100

The innovative bio-pharmaceutical group receives a much-needed injection of cash from American partner Baxter, which gets to appoint its own non-executive director to the Lipoxen board.

Lipoxen and Serum Institute of India start Phase II trial for ErepoXen

Mon, 01 Mar 2010 07:52:00 +0000

Results of the trial are scheduled to be reported early Q3 this year for the anaemia treatment.

Lipoxen granted EU patent for polysialic acid technology StimuXen

Mon, 08 Feb 2010 07:45:00 +0000

The technology, currently in pre-clinical development, aims at protecting the body’s level of white blood cells which is particularly beneficial in chemotherapy patients.

Lipoxen is filled to the brim with blockbuster drug potential

Thu, 11 Jun 2009 11:09:00 +0100

The CEO brings in a wealth of experience in the healthcare investment banking industry, the company’s three platform technologies have a impressive array of possible applications and routes to commercialisation and the shareholder register looks as solid as rock.